# Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy

Source: https://onco.cc/trials/nct07823049/  
OnCo record `nct07823049` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of XNW28012 for injection in pancreatic ductal adenocarcinoma, run by Evopoint Biosciences Inc., now recruiting.

## Summary

Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy is a phase 3 interventional study registered as NCT07823049 by Evopoint Biosciences Inc., with 226 participants planned, started 2025-07-08 and due to reach its primary completion in 2027-05-31. Interventions recorded: XNW28012 for injection and XNW28012 Mimetic for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07823049
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter Phase III Clinical Study Comparing XNW28012 Versus Placebo in Combination With Best Supportive Care in Patients With Metastatic Pancreatic Cancer Who Have Received Prior Systemic Therapy
- Sponsor: Evopoint Biosciences Inc.
- Enrolled: 226

## Sources

- ClinicalTrials.gov NCT07823049: https://clinicaltrials.gov/study/NCT07823049

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07823049.json